Article By:
The Fly
Thursday, June 8, 2017 3:48 PM EDT
While approval for Sarepta Therapeutic's Exondys 51 in the U.S. was controversial, Oppenheimer analyst Hartaj Singh said it has resulted in a "high level" of short interest and the company would be a "bargain" if it is acquired.